Nomogram Models Based on the Gene Expression in Prediction of Breast Cancer Bone Metastasis

Table 2

Cox regression analysis of the GESBN models and clinical variables in the training cohort.

Overall survival
Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
PR status	0.552 (0.363–0.838)	0.005	0.660 (0.398–1.094)	0.107
PES	0.644 (0.403–1.029)	0.066	0.649 (0.405–1.040)	0.073
Stage	1.006 (0.656–1.543)	0.979	1.214 (0.673–2.192)	0.519
Risk score	2.719 (1.663–4.447)	<0.001	2.289 (1.253–4.180)	0.007
Progression-free survival
PR status	0.598 (0.420–0.853)	0.004	0.807 (0.531–1.228)	0.317
PES	0.600 (0.395–0.912)	0.017	0.657 (0.424–1.016)	0.059
Stage	0.750 (0.517–1.088)	0.129	1.006 (0.604–1.674)	0.983
Risk score	2.710 (1.920–3.824)	<0.001	2.624 (1.757–3.919)	<0.001

abrAbbreviations: GESBN, gene expression signature-based nomogram; HR, hazard ratio; 95% CI, 95% confidence interval; PR status, progesterone receptor status; PES, prior endocrine sensitivity.